Antibodies
23 September 2011
Alexion Receives CHMP Positive Opinion for Soliris (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) in the European Union21 September 2011
Theraclone Sciences Announces Initiation of Phase 1 Clinical Trial of TCN-032 for Influenza A21 September 2011
New study finds rheumatoid arthritis (RA) patients preferred ergonomically designed Cimzia (certolizumab pegol) syringe to conventional prefilled syringe21 September 2011
Bristol-Myers Squibb and Ono Enter into Strategic Agreement for Anti-PD-1 Antibody, BMS-936558/ONO-4538, and ORENCIA (abatacept)21 September 2011
Glycotope Enrolls First Patients in Phase I Trial with TrasGEX, a Glycooptimized HER2 Biobetter Antibody20 September 2011
Fresenius Biotech’s Removab receives approval for a shorter infusion time in treating malignant ascites19 September 2011
Prolia (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment16 September 2011
Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis15 September 2011
Phase 2 Study of Eculizumab (Soliris) in Patients with Severe and Refractory Generalized Myasthenia Gravis Presented at MGFA Annual Meeting14 September 2011
MorphoSys Announces Clinical Milestone in Cancer Antibody Program with Bayer HealthCare Pharmaceuticals13 September 2011
VGX-100 Identified as Potential New Therapy for Dry Eye Disease13 September 2011
Thallion Provides Update on Phase II SHIGATEC Trial13 September 2011
Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer13 September 2011
Teva Announces Additional Investment in CureTech12 September 2011
FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI Supplemental Biologics License Application12 September 2011
Peregrine PS-Targeting Antibodies Show Broad Potential to Image Tumors and Assess Cancer Therapy Response9 September 2011
Sucampo and Numab Sign Drug Discovery Collaboration9 September 2011
F-Star and Merck Serono to Collaborate in the Discovery and Development of Novel Targeted Biologics8 September 2011
Protalix BioTherapeutics’ Taliglucerase Alfa Phase III Results Published in Blood, the Journal of the American Society of Hematology1 September 2011
MorphoSys Doses First Patient in Phase 1/2a Clinical Trial for MOR202 Program in Multiple Myeloma1 September 2011
AnaptysBio Successfully Generates Therapeutic Antibodies in Partnership with a Leading Global Pharma31 August 2011
Richter and STADA cooperate for development of two biosimilar products, two monoclonal antibodies: Rituximab and TrastuzumabNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports